Jade Biosciences, Inc. JBIO
Set alert
13.64 USD -0.42 -2.99%
As of Nov 2, 12:07 PM ET
13.55 Day range 14.44
8.36 52-week range 28.00
- YTD
- -11.60%
- 1 year
- +39.18%
- Open
- 14.44
- Prev close
- 14.06
- Mkt cap
- 867.47M
- Vol
- 197.91K
- Avg vol
- 898.85K
- EPS
- -1.92
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.55
- High
- 14.44
- Forward P/E
- -6.29
- Beta
- 0.00
- Short ratio
- 12.92
- Inst. own
- 116.01%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 20.55
- 200-d avg
- 18.29
- 1y target
- 50.13
Financial health
Altman Z-Score
15.41 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 3
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 2
Valuation
P/E -3.8×
FY 2020 5y median -7.9× FY 2025
P/S 0.0×
FY 2020 5y median 0.0× FY 2025
P/B 1.5×
FY 2020 5y median 1.7× FY 2025
P/FCF -5.1×
FY 2020 5y median -10.4× FY 2025
EV/EBITDA -3.1×
FY 2020 5y median -7.6× FY 2025
EV/Sales 0.0×
FY 2020 5y median 0.0× FY 2025
FCF Yield -19.6%
FY 2020 5y median -9.6% FY 2025
Profitability
Gross Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2020 5y median 0.0% FY 2025
ROE -38.3%
FY 2020 5y median -40.6% FY 2025
ROIC -34.1%
FY 2020 5y median -41.6% FY 2025
ROA -36.4%
FY 2020 5y median -38.1% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2020 FY 2025
Operating Income -52.2%
FY 2020 FY 2025
EPS (diluted) 95.2%
FY 2020 FY 2025
Free Cash Flow -33.3%
FY 2020 FY 2025
Financial Health
Current Ratio 20.3×
FY 2020 5y median 20.3× FY 2025
Quick Ratio 20.3×
FY 2020 5y median 20.3× FY 2025
Debt / Equity 0.0×
FY 2020 5y median 0.0× FY 2025
Net Debt / EBITDA 0.7×
FY 2020 5y median 0.5× FY 2025
Interest Coverage 0.0×
FY 2020 5y median 0.0× FY 2025
Dividends
Dividend Yield 15.6%
FY 2020 5y median 0.0% FY 2025
Payout Ratio -59.1%
FY 2020 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31